No significant associations were seen between caregiver QoL and glioblastoma recurrence, baseline Karnofsky performance status, surgery at diagnosis, number or site of lesions, tumor MGMT status, TERT and IDH1 mutation status, MGMT methylation and IDH1 mutation status, or IDH1 mutation status alone. This evidence concerns the gene MGMT and glioblastoma.